Finn et al 1 comment in their Letter on the morphological and phenotypic heterogeneity of human atherosclerotic plaque macrophages. Atherosclerosis has long been considered as a predominantly T H 1-driven disease. The evidence for the presence of alternative M2 macrophages in human atherosclerotic plaques is relatively recent. 2 Macrophages are plastic versatile cells that adapt their function/phenotype to the microenvironment. The inflammatory response driven by classically activated M1 macrophages is usually counteracted by protective mechanisms operated by the alternative M2 macrophages. In a highly simplified scheme, M1 macrophages are defined as cells activated by bacterial lipopolysaccharide or T H 1 cytokines, such as tumor necrosis factor, whereas M2 macrophages are typically induced by T H 2 cytokines, such as IL-4 and IL-13. However, the spectrum of macrophage phenotypes is more complex. For instance, M2 macrophages are further subdivided in three different subclasses: 3 IL-4 and IL-13 drive the M2a macrophage phenotype, immune complexes combined to IL-1␤ or lipopolysaccharide promote the M2b subtype, and IL-10, transforming growth factor-␤, or glucocorticoids induce M2c-type macrophages. M2 macrophages are generally characterized by high IL-10 and transforming growth factor-␤ (especially prominent in M2c) and low IL-12 production and high endocytic clearance capacities, hence protecting surrounding tissues from a detrimental immune response. An exception is the M2b macrophages, which are functionally anti-inflammatory, but they still produce high amounts of inflammatory cytokines. 4 However, this classification represents extremes of macrophage activation states and probably simplifies the in vivo situation, in which the full phenotypic spectrum between M1 and M2 can exist. 5 Thus, the findings of Finn et al, 6 Boyle et al, 7 and our own (unpublished) identifying M2 macrophages with slightly distinct phenotypes in zones of intraplaque hemorrhage are a further illustration of this heterogeneity.
Response to the Letter by Finn et al
Response:
Finn et al 1 comment in their Letter on the morphological and phenotypic heterogeneity of human atherosclerotic plaque macrophages. Atherosclerosis has long been considered as a predominantly T H 1-driven disease. The evidence for the presence of alternative M2 macrophages in human atherosclerotic plaques is relatively recent. 2 Macrophages are plastic versatile cells that adapt their function/phenotype to the microenvironment. The inflammatory response driven by classically activated M1 macrophages is usually counteracted by protective mechanisms operated by the alternative M2 macrophages. In a highly simplified scheme, M1 macrophages are defined as cells activated by bacterial lipopolysaccharide or T H 1 cytokines, such as tumor necrosis factor, whereas M2 macrophages are typically induced by T H 2 cytokines, such as IL-4 and IL-13. However, the spectrum of macrophage phenotypes is more complex. For instance, M2 macrophages are further subdivided in three different subclasses: 3 IL-4 and IL-13 drive the M2a macrophage phenotype, immune complexes combined to IL-1␤ or lipopolysaccharide promote the M2b subtype, and IL-10, transforming growth factor-␤, or glucocorticoids induce M2c-type macrophages. M2 macrophages are generally characterized by high IL-10 and transforming growth factor-␤ (especially prominent in M2c) and low IL-12 production and high endocytic clearance capacities, hence protecting surrounding tissues from a detrimental immune response. An exception is the M2b macrophages, which are functionally anti-inflammatory, but they still produce high amounts of inflammatory cytokines. 4 However, this classification represents extremes of macrophage activation states and probably simplifies the in vivo situation, in which the full phenotypic spectrum between M1 and M2 can exist. 5 Thus, the findings of Finn et al, 6 Boyle et al, 7 and our own (unpublished) identifying M2 macrophages with slightly distinct phenotypes in zones of intraplaque hemorrhage are a further illustration of this heterogeneity.
In our article published in Circulation Research, 8 we identified yet another CD68 ϩ MR ϩ macrophage subpopulation located distant from both the lipid core and hemorrhagic zones, containing smaller lipid droplets compared to the CD68 ϩ MR Ϫ macrophages around the lipid core. Moreover, we found an enrichment of CD3 ϩ T-lymphocytes in areas infiltrated by the CD68 ϩ MR ϩ macrophages associated with gene expression of IL-4, an M2 macrophage inducer primarily produced by T H 2 lymphocytes. These observations confirm the existence of M2 macrophages in human atherosclerotic plaques and suggest, but do not prove, the nature of the generating stimulus, an inherent limitation of correlation studies on human tissues.
To functionally characterize these M2 macrophages, we developed a model of in vitro IL-4 polarized macrophages. IL-4 polarized CD68 ϩ MR ϩ macrophages are less competent to uptake native and oxidized lipoproteins, likely because of the reduced expression of LOX-1 and caveolin-1, which provide a mechanism for the absence of lipid accumulation in these cells. Simultaneously, these cells display lower cholesterol efflux capacities because of low expression of the nuclear receptor liver X receptor-␣ and its target genes, ABCA1 and apolipoprotein E. By contrast, both these in vivo and in vitro CD68 ϩ MR ϩ macrophages express high levels of opsonins and receptors involved in phagocytosis, resulting in high phagocytic activity, which is enhanced by activation of the peroxisome proliferatoractivated receptor-␥. 8 Our in vitro polarized M2 macrophages, showing the existence of cell-intrinsic functional differences in terms of lipid accumulation and storage, resemble the phenotype of the macrophages resident in atherosclerotic plaques, thus validating our approach. The reduced expression of ABCA1 observed in our experiments is in line with previous findings in IL-4 polarized macrophages. 9 The interesting findings of Finn et al identifying a subpopulation of CD68 ϩ MR ϩ CD163 ϩ alternative M2 macrophages enriched in areas of hemorrhage, induced by the hemoglobin/ haptoglobin complex, producing anti-inflammatory factors and devoid of lipid accumulation because of enhanced cholesterol efflux, are not inconsistent with our findings; however, they illustrate the complex phenotype atherosclerotic plaque macrophages may display as well as the different mechanisms involved. 6 Considering that the cytokine milieu is complex and varies during the different stages of atherosclerotic plaque progression, it is likely that intermediate spectra of differentiation states exist. In addition, we also believe that spatial localization can affect the macrophage phenotype. The phenotype of the alternative macrophage population present in hemorrhagic areas identified by Finn et al can be different from those of alternative macrophages identified by us or from other CD68 ϩ MR ϩ macrophages located elsewhere in the plaque.
Although significant progress has been made in characterizing the phenotype and functions of macrophage subpopulations during atherosclerosis development, much remains to be discovered. Investigations of the role of these different macrophage subpopulations in the pathophysiology of atherosclerosis and other vascular diseases, such as abdominal aortic aneurysms, remain a challenging field of research. We agree with Finn et al that the identification of the endogenous factors controlling the balance of classical/alternative macrophage polarization and other subtypes within the atherosclerotic plaques represents an exciting area of future research that may lead to potential therapeutic applications. 
